Navigation Links
Lilly and Amylin Set Date and Time for Conference Call
Date:8/25/2008

Companies Will Discuss Recent FDA Advisory Regarding Byetta

INDIANAPOLIS, Aug. 25 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will host a conference call on Tuesday, August 26, 2008 at 5:00 p.m. EDT to discuss the recent FDA advisory on Byetta(R) (exenatide) injection. Participating in the call for Lilly will be Donald Therasse, M.D., vice president of global patient safety. Participating in the call for Amylin will be Daniel M. Bradbury, Amylin's president and chief executive officer, and Orville G. Kolterman, M.D., senior vice president of research and development.

Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at http://www.lilly.com or Amylin's website at http://www.amylin.com The webcast of the conference call will be available for replay through September 26, 2008. For those without access to the Internet, the live call may be accessed by phone by calling (866) 814-1915 (domestic) or (703) 639-1359 (international), passcode 1277182. A replay of the call will also be available by phone through September 26, 2008 beginning approximately one hour after the close of the call and can be accessed at (888) 266-2081 (domestic) or (703) 925-2533 (international), passcode 1277182.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com. P-LLY

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help health care professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients. For more information about Lilly's current diabetes products visit http://www.lillydiabetes.com.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYAMYLINLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... announces the continuation of its strategic partnership with and platinum sponsorship of Global ... in the safe and effective management of complex spine deformity cases, particularly in ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Michael Vick ... and transforming the quarterback position. The former overall number one pick in the 2001 ... football career. He holds the record for the most career rushing yards by a ...
(Date:4/24/2017)... , ... April 24, 2017 , ... As part of ... today to honor the victims of the Holocaust and Nazi persecution, Center for ... Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland next week. ...
(Date:4/24/2017)... ... ... Pink , a national non-profit organization focusing on the prevention and early detection of breast ... proud to announce Katie Thiede as their new Chief Executive Officer. In January, founder Lindsay ... the Board and launched a national search to find a visionary new leader to grow ...
(Date:4/24/2017)... ... ... Veteran Theresa James awoke to the sound of her newly ex-husband breaking ... James depicts every parent’s worst nightmare, when her three children were violently taken from ... throughout my divorce,” James said. “After the death of my children, I continued to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Ind. , April 20, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Care Conference at the InterContinental Hotel in ... Zimmer Biomet will present at 11:20 a.m. Eastern Time. ... be accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: